Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
piragrel sodium
- Development stage
- Phase 3
- Lead developer
- Hefei Medical and Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Piragrel sodium is a small molecule drug under clinical investigation as an antiplatelet agent. It is being developed primarily for the treatment of acute ischemic stroke. Piragrel sodium acts as a platelet aggregation inhibitor, similar in therapeutic intent to thienopyridine-class antiplatelet drugs, but it is chemically distinct from agents like prasugrel or clopidogrel. The drug is administered intravenously and has been evaluated in multicenter, randomized, double-blind, placebo-controlled phase II and III clinical trials for its efficacy and safety in patients with acute ischemic stroke within 48 hours of onset[6]. Its mechanism involves inhibition of platelet aggregation to reduce thrombotic events associated with cerebral infarction.
- Other names
- pyragrel sodium吡拉格雷钠 (Chinese name)
02
Targets
TBXAS1 (Thromboxane A2 synthase)
Beyond the preview
Go deeper on piragrel sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on piragrel sodium.